SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib

Thomas O'Hare, Christopher A. Eide, Jeffrey W. Tyner, Amie S. Corbin, Matthew J. Wong, Sean Buchanan, Kevin Holme, Katayoun A. Jessen, Crystal Tang, Hal A. Lewis, Richard D. Romero, Stephen K. Burley, Michael W. Deininger

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Fingerprint

Dive into the research topics of 'SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib'. Together they form a unique fingerprint.

Medicine & Life Sciences